The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Nomani AZ, Qureshi MS, Barki UF, Wazir M, Kashmir SB, Nomani H

Pegylated-interferon induced interstitial pneumonitis.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2014;24(3):219-20

Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A, Chuang WL, Lee CM, George J, Gould M, Flisiak R, Jacobson IM, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Sola R, Messina I, Yin Y, Cammarata S, Feutren G, Brown KK

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.

Journal of viral hepatitis. 2013;20(4):e115-23

Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M

Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C.

World journal of gastroenterology. 2010;16(35):4394-9

Slavenburg S, Heijdra YF, Drenth JP

Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature.

Digestive diseases and sciences. 2010;55(3):579-85

Carrillo-Esper R, González-Avila D, Uribe-Ríos M, Méndez-Sánchez N

Interstitial pneumonitis associated with pegylated interferon alpha-2b therapy for chronic hepatitis C: case report.

Annals of hepatology. 2008;7(1):87-90

Siegelmann-Danieli N, Bardo M, Law A, Fisk D, Bernath A Jr

Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.

The Israel Medical Association journal : IMAJ. 2004;6(10):636-7

Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, Jacobson IM, Brown RS Jr

Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.

The American journal of gastroenterology. 2002;97(9):2432-40

Karim A, Ahmed S, Khan A, Steinberg H, Mattana J

Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.

The American journal of the medical sciences. 2001;322(4):233-5

Yufu Y, Yamashita S, Nishimura J, Nawata H, Hirata J

Interstitial pneumonia caused by interferon-alpha in chronic myelogenous leukemia.

American journal of hematology. 1994;47(3):253

Stevenson HC, Ochs JJ, Halverson L, Oldham RK, Sherwin SA, Foon KA

Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications.

The American journal of medicine. 1984;77(2):355-8